| scholarly article | Q13442814 |
| P50 | author | Steven Rosenberg | Q2347448 |
| Anusha Kalbasi | Q57620683 | ||
| P2093 | author name string | Rajeev K Shrimali | |
| Dhanalakshmi Chinnasamy | |||
| P2860 | cites work | Single and dual amino acid substitutions in TCR CDRs can enhance antigen-specific T cell functions | Q36713758 |
| Transduction of an IL-2 gene into human melanoma-reactive lymphocytes results in their continued growth in the absence of exogenous IL-2 and maintenance of specific antitumor activity | Q36726945 | ||
| In vivo administration of purified human interleukin 2. II. Half life, immunologic effects, and expansion of peripheral lymphoid cells in vivo with recombinant IL 2. | Q40815147 | ||
| The use of anti-CD3 and anti-CD28 monoclonal antibodies to clone and expand human antigen-specific T cells | Q41736991 | ||
| Suspension packaging cell lines for the simplified generation of T-cell receptor encoding retrovirus vector particles. | Q45865231 | ||
| Retroviral transduction of human peripheral blood lymphocytes with Bcl-X(L) promotes in vitro lymphocyte survival in pro-apoptotic conditions | Q45885040 | ||
| IL-2 addiction: withdrawal of growth factor activates a suicide program in dependent T cells. | Q52267043 | ||
| Genes regulating HLA class I antigen expression in T-B lymphoblast hybrids. | Q53436850 | ||
| Inhibition of Fas-induced apoptosis by Bcl-2. | Q54114172 | ||
| Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients | Q69548004 | ||
| Tumor-specific cytolysis by lymphocytes infiltrating human melanomas | Q69738303 | ||
| Immunotherapy through TCR gene transfer | Q74569068 | ||
| Expression of Bcl-2, Bcl-x, and Bax after T cell activation and IL-2 withdrawal | Q24328947 | ||
| IL-15 enhances the in vivo antitumor activity of tumor-reactive CD8+ T cells | Q24621753 | ||
| Gene therapy with human and mouse T-cell receptors mediates cancer regression and targets normal tissues expressing cognate antigen | Q24623215 | ||
| Adoptive cell therapy for patients with metastatic melanoma: evaluation of intensive myeloablative chemoradiation preparative regimens | Q24644442 | ||
| Adoptive cell transfer: a clinical path to effective cancer immunotherapy | Q24644774 | ||
| Cancer regression in patients after transfer of genetically engineered lymphocytes | Q24654976 | ||
| BCL-2, BCL-X(L) sequester BH3 domain-only molecules preventing BAX- and BAK-mediated mitochondrial apoptosis | Q28189945 | ||
| The BCL-2 protein family: opposing activities that mediate cell death | Q29547380 | ||
| Acquisition of full effector function in vitro paradoxically impairs the in vivo antitumor efficacy of adoptively transferred CD8+ T cells | Q33831940 | ||
| Dysregulation of apoptosis genes in hematopoietic malignancies. | Q34658574 | ||
| Role of Bcl-2 family of proteins in malignancy | Q34733047 | ||
| Modulation by IL-2 of CD70 and CD27 expression on CD8+ T cells: importance for the therapeutic effectiveness of cell transfer immunotherapy | Q34936175 | ||
| Genetic modification of T lymphocytes for adoptive immunotherapy | Q35826514 | ||
| Adoptive transfer of effector CD8+ T cells derived from central memory cells establishes persistent T cell memory in primates | Q36183567 | ||
| Adoptive cell therapy for the treatment of patients with metastatic melanoma | Q36283034 | ||
| Bcl-2 overexpression enhances tumor-specific T-cell survival | Q36327125 | ||
| Primary human lymphocytes transduced with NY-ESO-1 antigen-specific TCR genes recognize and kill diverse human tumor cell lines | Q36327142 | ||
| Cutting edge: persistence of transferred lymphocyte clonotypes correlates with cancer regression in patients receiving cell transfer therapy | Q36328394 | ||
| Tumor regression and autoimmunity after reversal of a functionally tolerant state of self-reactive CD8+ T cells. | Q36371632 | ||
| P433 | issue | 7 | |
| P304 | page(s) | 672-683 | |
| P577 | publication date | 2010-09-01 | |
| P1433 | published in | Journal of Immunotherapy | Q15763946 |
| P1476 | title | Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein | |
| P478 | volume | 33 |
| Q38227889 | A new hope in immunotherapy for malignant gliomas: adoptive T cell transfer therapy |
| Q38178359 | Adoptive immunotherapy for cancer or viruses |
| Q27027803 | Advances in the treatment of metastatic melanoma: adoptive T-cell therapy |
| Q37851972 | Cellular immunotherapy for high-grade glioma |
| Q35149637 | Classification of current anticancer immunotherapies |
| Q26995677 | Genetic engineering with T cell receptors |
| Q26860657 | Genetically modified T cells for the treatment of malignant disease |
| Q28081611 | T-cell receptor gene therapy--ready to go viral? |
| Q36887833 | Trial Watch: Adoptive cell transfer for anticancer immunotherapy |
| Q42702234 | Trial Watch: Adoptive cell transfer for anticancer immunotherapy |
| Q26785545 | Trial Watch: Adoptive cell transfer for oncological indications |
| Q36057432 | Trial Watch: Adoptive cell transfer immunotherapy |
Search more.